期刊文献+

去势抵抗性前列腺癌治疗进展 被引量:2

原文传递
导出
摘要 前列腺癌(Prostate cancer,PCa)是目前常见的男性恶性肿瘤之一。传统治疗方案是去势治疗(Androgen deprivation therapy,ADT),也称为雄激素剥夺治疗,包括药物去势和手术去势,其目的在于通过阻断雄激素和雄激素受体(Androgen receptor,AR)结合的机制抑制肿瘤的生长,降低前列腺特异性抗原(Protate specific antigen,PSA),提高患者生活质量以及延长生存时间。
出处 《中国冶金工业医学杂志》 2018年第2期144-145,共2页 Chinese Medical Journal of Metallurgical industry
  • 相关文献

参考文献2

二级参考文献57

  • 1Siegel R, Ward E, Brawley 0, et al. Cancer statistics, 2011: Theimpact of eliminating socioeconomic and racial disparities on pre-mature cancer deaths [J].CA Cancer J Clin,2011,61(4):212-236.
  • 2Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mito-xantrone plus prednisone or prednisone alone for symptomatic hor-mone-resistant prostate cancer: A Canadian randomized trial withpalliative end points [J].J Clin Oncol, 1996,14(6): 1756-1764.
  • 3Berthold DR, Pond GR, de Wit R, et al. Survival and PSA re-sponse of patients in the TAX 327 study who crossed over to re-ceive docetaxel after mitoxantrone or vice versa [J].Ann Oncol,2008,19(10):1749-1753.
  • 4Kelly WK, Halabi S, Carducci M, et al. Randomized, dou-ble-blind, placebo-controlled phase III trial comparing docetaxeland prednisone with or without bevacizumab in men with metastat-ic castration-resistant prostate cancer: CALGB 90401 [J].J Clin0ncol.2012,30(13):1534-1540.
  • 5Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estra-mustine compared with mitoxantrone and prednisone for advancedrefractory prostate cancer [J].N Engl J Med,2004,351(15):1513-1520.
  • 6Sternberg CN,Petrylak DP, Sartor O, et al. Multinational, dou-ble-blind, phase III study of prednisone and either satraplatin orplacebo in patients with castrate-refractory prostate cancer pro-gressing after prior chemotherapy: The SPARC trial [J].J Clin On-col,2009,27(32):5431-5438.
  • 7De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazi-taxel or mitoxantrone for metastatic castration-resistant prostatecancer progressing after docetaxel treatment: A randomizedopen-label trial [J].Lancet,2010,376(9747): 1147-1154.
  • 8Reid AH, Attard G, Danila DC, et al. Significant and sustained an-titumor activity in post-docetaxel, castration-resistant prostate can-cer with the CYP17 inhibitor abiraterone acetate [J].J Clin Oncol,2010,28(9):1489-1495.
  • 9De Bono JS, Logothetis CJ, Molina A,et al. Abiraterone and in-creased survival in metastatic prostate cancer [J].N Engl J Med,2011,364(21):1995-2005.
  • 10KantoffPW, Higano CS, Shore ND, et al. Sipuleucel-T immuno-therapy for castration-resistant prostate cancer [J].N Engl J Med,2010,363(5): 411-422.

共引文献21

同被引文献21

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部